Dr Gao Fu (Photo from Global Times)

Concern is mounting that China’s COVID-19 vaccines are less effective raising questions about countries using Chinese vaccines and their inoculation drive, according to a report from Bloomberg.

While vaccines developed by Pfizer and Moderna and even Russia’s Sputnik have delivered protection rates of more than 90 per cent, the Chinese vaccines have generally reported much lower efficacy results.

Presently, Sinovac’s vaccine used in Indonesia and Brazil was reported to be just just above 50 per cent effective. This figure barely meets the minimum protection required for COVID-19 vaccines by leading global drug regulators. Other Chinese vaccines have reported efficacy rates of between 66 per cent and 79 per cent.

What’s worse is that, in the case of Sinovac, its CEO has been caught bribing China’s own vaccine regulator for years. The CEO was never punished but the deputy director of the China Food and Drug Administration’s drug-testing center was jailed instead (‘Sinovac CEO caught for bribing Chinese regulator remains unscathed and continues to oversee COVID-19 vaccine development‘). The incident raises questions with regard to ethics of Chinese firms producing vaccines.

With regard to Sinovac, Singapore has already purchased and received a shipment of Sinovac’s vaccines but has yet to approve it.

Chinese CDC’s head laments over low efficacy of their vaccines

In any case, anxiety over Chinese vaccines spilled into the open at the weekend when Dr Gao Fu, head of the Chinese Centre for Disease Control and Prevention, said at a forum that something needs to be done to address the low protection rate of the Chinese vaccines, according to local news media.

The rare admission by a senior official went viral on social media before China’s censors swung into action, taking down posts and media reports on Gao’s comments.

Then, Gao backtracked and went public on state-controlled Global Times newspaper on Sunday (11 Apr) saying that his remarks were misinterpreted and were meant only to suggest ways to improve the efficacy of vaccines.

He suggested that following up inoculations with additional booster shots and mixing different types of vaccines could help tackle the effectiveness issue, according to the Global Times.

The concerns put a question mark over many developing countries like Turkey and Indonesia using the Chinese developed vaccines.

Meanwhile, it has been reported that China is also developing its own vaccines based on the new mRNA technology used by Pfizer and Moderna. The Chinese made mRNA vaccines are expected to be ready by the end of this year, the report said.

Subscribe
Notify of
2 Comments
Newest
Oldest Most Voted
Inline Feedbacks
View all comments
You May Also Like

教育规划让学生发挥所长 总理称续确保教育可负担、高素质

李显龙总理在本周日(5日)的一项活动上强调教育对国家未来之重要,且教育体制是规划为让每个学生都能发挥最好一面。 他也重申不应让国人因为成本而延缓追求教育,故此目前确保每个人都负担得起。 总理在昨日出席其选区宏茂桥德义区教育储蓄奖励金颁奖礼,向在场城景小学师生这么指出。李显龙也是该集选区议员。 本地中学生的普通和快捷源流之区分,将在2024年结束。2024年入学的中一学生,将依据他们的程度和强项来选读适合的科目程度。 作为措施的一部分,大约25所中学将在今年试跑科目编班全面计划,并逐年增加参与学校。 至于小六会考(PSLE)评估则着重学生个人表现、不过分强调学术成绩,学生无论起跑点在哪,都能拓展自己的兴趣和所长潜能。 他表示教育是政府关注的重要事项之一,政府相信透过教育让公民学习技能和知识,成为有成效、可自力更生的良才。 而在昨日总理也办法了德义公民咨询委会助学金,以及教育部储蓄奖,予1100名学生。教育部储蓄奖(Edusave award)依据学生的领导才能、品行或学业成绩颁发,得奖学生约能领取200至500新元的奖励。 至于助学金则是由基层组织筹措。 总理在致辞中也表示政府将继续支援学生,确保教育系统保持高素质和可负担。

HDB policy on singles: Singaporean vs Permanent Resident

Leong Sze Hian Why are Permanent Residents (PRs) who are single buying…

Australia is defamation capital of the world, so why doesn’t PM Lee sue States Times Review for publishing allegations?

Australia has become the defamation capital of the world, said New York…